Pipeline

Our first asset in clinical development is for high-risk neuroblastoma. This will be the first in our pipeline of clinical-stage products which are targeted to make a meaningful difference for patients in niche populations, who might otherwise be overlooked.

Hu14.18 for neuroblastoma
Hu14.18K322A (Hu14.18) is a humanised, anti-GD2 antibody immunotherapy under development by Essential Pharma for the treatment of high-risk neuroblastoma (HRNB), a rare childhood cancer. Neuroblastoma represents 7-10% of all childhood cancers and is the most common extracranial cancer in children and the most common cancer in children under one year of age. Approximately half of all neuroblastoma patients have high-risk disease which has an overall survival of ~50% over five years.

Hu14.18 has been designed to potentially reduce immunogenicity, increase cell kill activity and limit off-target effects to provide a treatment that will improve efficacy and tolerability in patients.

Phase I and II trials have shown the treatment to be tolerable and clinically active in a variety of settings within HRNB – Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A – PubMed.